Other Events ·
DARPA awards NRx Defense Systems $11.2M contract for depression clinical trial
NRXPNRX Pharmaceuticals, Inc.
NRx Pharmaceuticals subsidiary NRx Defense Systems entered into a prime contract with the Defense Advanced Research Projects Agency (DARPA) valued at approximately $11.2 million to conduct the SPARC-TMS clinical trial. The agreement includes an initial obligation of $6.7 million, with additional funding subject to appropriations and option exercises over an 18-month performance period. The trial evaluates a single-day robotic transcranial magnetic stimulation protocol combined with investigational drug NRX-101 for treatment-resistant depression. FDA approval has been granted, and patient enrollment is expected to begin shortly at sites including Harvard Medical School’s McLean Hospital. NRx Pharmaceuticals operates as a clinical-stage biopharmaceutical company developing therapeutics for central nervous system disorders.